{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:14:37Z","timestamp":1776899677732,"version":"3.51.2"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.hoc.2019.03.005","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T02:14:04Z","timestamp":1557454444000},"page":"687-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Bradley D.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","article-title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas","volume":"132","author":"Schmitz","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.005_bib2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2019.03.005_bib3","unstructured":"Mamez A, Dupont A, Blaise D, et\u00a0al. Allogeneic stem cell transplantation for peripheral T-cell lymphomas: a study of 284 patients from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire. 44th Annual Meeting of the EBMT. Lisbon, March 18-21, 2018."},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.005_bib5","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.005_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.hoc.2019.03.005_bib7","first-page":"8507","article-title":"Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial","volume":"33","author":"Schmitz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.005_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","volume":"182","author":"Kanate","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.005_bib9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2019.03.005_bib10","first-page":"4597","article-title":"Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis","volume":"130","author":"Mehta-Shah","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.005_bib12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.005_bib13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/bmt.2016.313","article-title":"Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia\/lymphoma, a Japanese nation-wide study","volume":"52","author":"Fujiwara","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"29","key":"10.1016\/j.hoc.2019.03.005_bib15","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2019.03.005_bib16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2016.282","article-title":"Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation","volume":"52","author":"van Gelder","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.005_bib18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bmt.2016.329","article-title":"Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation","volume":"52","author":"Schetelig","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.005_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2019.03.005_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.hemonc.2017.05.004","article-title":"Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances","volume":"10","author":"Epperla","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"20","key":"10.1016\/j.hoc.2019.03.005_bib21","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.005_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.005_bib23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.005_bib24","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.005_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study","volume":"91","author":"Rigacci","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bmt.2015.223","article-title":"Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma","volume":"51","author":"Klyuchnikov","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.005_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbmt.2017.10.013","article-title":"Double-expressor lymphoma is associated with poor outcomes after allogeneic hematopoietic cell transplantation","volume":"24","author":"Kawashima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbmt.2017.11.023","article-title":"Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma","volume":"24","author":"Herrera","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.hoc.2019.03.005_bib29","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2019.03.005_bib31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T\u00a0cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"215","key":"10.1016\/j.hoc.2019.03.005_bib33","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib34","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T\u00a0cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2019.03.005_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","author":"Lin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2019.03.005_bib36","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.005_bib37","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A\u00a0large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.005_bib38","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.005_bib39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.005_bib40","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience","volume":"143","author":"Rezvani","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.005_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbmt.2008.04.007","article-title":"Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma","volume":"14","author":"Kuruvilla","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.005_bib43","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pinana","year":"2010","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2019.03.005_bib44","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2019.03.005_bib45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.hoc.2019.03.005_bib46","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.005_bib47","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ajh.23246","article-title":"Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma","volume":"87","author":"Tada","year":"2012","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.hoc.2019.03.005_bib48","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2019.03.005_bib49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.005_bib50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","article-title":"Allotransplantation for patients age\u00a0>\/=40 years with non-Hodgkin lymphoma: encouraging progression-free survival","volume":"20","author":"McClune","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2019.03.005_bib51","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/bmt.2015.158","article-title":"Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed\/refractory follicular lymphoma","volume":"50","author":"Yano","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2019.03.005_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2014.10.024","article-title":"Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation","volume":"21","author":"Cassaday","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.hoc.2019.03.005_bib53","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.bbmt.2016.04.014","article-title":"Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the blood and marrow transplant clinical trials network","volume":"22","author":"Laport","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13931","article-title":"The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2019.03.005_bib55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-017-2934-9","article-title":"Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases","volume":"96","author":"Picleanu","year":"2017","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2019.03.005_bib56","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bbmt.2017.03.031","article-title":"Allogeneic stem cell transplantation for relapsed\/refractory B cell lymphomas: results of a multicenter phase II prospective trial including rituximab in the reduced-intensity conditioning regimen","volume":"23","author":"Dodero","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2018.07.038","article-title":"Reduced-intensity conditioning followed by related and unrelated allografts for hematologic malignancies: expanded analysis and long-term follow-up","volume":"25","author":"Warlick","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2019.03.005_bib58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2019.03.005_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A\u00a0comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2019.03.005_bib61","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"355","key":"10.1016\/j.hoc.2019.03.005_bib62","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.hoc.2019.03.005_bib63","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T\u00a0cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:11:07Z","timestamp":1760184667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858819300383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0889858819300383"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.03.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}